Abstract
This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carriers. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.
Original language | English |
---|---|
Pages (from-to) | 211-215 |
Number of pages | 5 |
Journal | Journal of Viral Hepatitis |
Volume | 3 |
Issue number | 4 |
Publication status | Published - Jul 1996 |
Keywords
- Famciclovir
- Hepatitis B virus
- Nucleoside analogue